期刊
TARGETED ONCOLOGY
卷 11, 期 2, 页码 235-238出版社
SPRINGER
DOI: 10.1007/s11523-015-0384-7
关键词
-
类别
资金
- Russian Scientific Fund [14-15-00528]
- Russian Science Foundation [14-15-00528] Funding Source: Russian Science Foundation
Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据